why choose us

First received: June 09, 2023

Clinical Trial: A Study of FRaDCs for Ovarian Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Fallopian Tube Carcinosarcoma

Study Type: INTERVENTIONAL


Official Title: FR?DCs Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer

Brief Summary: The purpose of this study is to determine the response rate to the combination of folate receptor alpha dendritic cells (FRaDCs) plus pembrolizumab in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer.Vaccines made from a person's peptide treated white blood cells may help the body build an effective immune response to kill tumor cells.

Read more